Zydus Lifesciences Ltd

Zydus Lifesciences announced that ESG Risk Assessments and Insights (ESGRAIL), a SEBI registered ESG Rating Provider has assigned overall ESG rating of 68 (last year 66) to the Company.

Zydus Lifesciences Ltd gained for a fifth straight session today. The stock is quoting at Rs 907, up 1.73% on the day as on 12:39 IST on the NSE. The benchmark NIFTY is down around 0.59% on the day, quoting at 23855.35. The Sensex is at 76913.19, down 0.84%. Zydus Lifesciences Ltd has slipped around 1.74% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has slipped around 4.54% in last one month and is currently quoting at 21991.2, up 0.94% on the day. The volume in the stock stood at 3.71 lakh shares today, compared to the daily average of 6.62 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 908, up 1.63% on the day. Zydus Lifesciences Ltd is up 4.39% in last one year as compared to a 4.5% spurt in NIFTY and a 8.48% spurt in the Nifty Pharma index.The PE of the stock is 19.1 based on TTM earnings ending December 25.

The drug is the generic version of Farxiga' Tablets, 5 mg and 10 mg. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The tablets will be manufactured at the group's formulation facility at SEZ, Ahmedabad. According to IQVIA MAT February 2026 data, Dapagliflozin tablets had annual sales of $10.2 billion in the United States. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity. The group now has 436 USFDA approvals and has filed 505 ANDAs since it began filing in FY2003-04. Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products. The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga' Tablets, 5 mg and 10 mg). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets, 5 mg and 10 mg. Dapagliflozin tablets will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad. Dapagliflozin tablets had annual sales of USD 10.2bn in the United States (IQVIA MAT February 2026).

The company said the Drug Controller General of India (DCGI) had earlier approved the manufacturing and marketing of the Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications. Zydus stated that, unlike existing treatment options that require patients to purchase multiple single-dose pens during dose titration, it is offering a reusable multi-dose pen device. This innovation allows patients and clinicians to select and administer different dose strengths from a single pen, which the company claims will improve adherence, enhance convenience, and reduce overall treatment costs. The semaglutide injection will be available in a 15 mg/3 ml cartridge and will be manufactured at Zydus Biotech Park in Ahmedabad. The company said the average monthly cost of therapy is expected to be around Rs 2,200. Zydus also highlighted that diabetes and obesity are major public health challenges in India. Citing the International Diabetes Federation, it noted that 8.9 crore adults in India are living with diabetes, representing 10.5% of the adult population. The company further pointed out a sharp rise in obesity prevalence among adults, increasing by 91% in women and 146% in men, underscoring the growing burden of lifestyle-related diseases in the country. Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products. The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25. Shares of Zydus Lifesciences rose 1.63% to settle at Rs 890.60 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences has launched Semaglutide Injection under the brand names ' SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications. Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, Zydus offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost. Zydus' Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of the treatment will be approximately Rs. 2,200.Powered by Capital Market - Live

Aerolife Mini is India's first portable and foldable spacer, designed for convenience and ease of use. The device has been launched under an exclusive licensing agreement with AeroDel Technology Innovations. According to the company, India faces a growing burden of chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis, driven by factors such as rising air pollution, smoking, recurrent infections, and delayed diagnosis. Millions of patients rely on long-term inhaled therapies to control symptoms and maintain quality of life. While inhaled medications are central to treatment, effective delivery remains a challenge. Real-world studies indicate that nearly 94% of patients make at least one critical inhaler technique error, reducing drug efficacy. Spacer devices improve lung deposition by reducing coordination errors, but most existing products are bulky, difficult to transport, and require repeated assembly, limiting adherence. Aerolife Mini' addresses these limitations with a compact, foldable, ready-to-use design, aiming to improve drug deposition, enhance compliance, boost patient confidence, and provide greater convenience. This launch aligns with Zydus Lifesciences's long-term strategy of building innovation-led, patient-centric respiratory franchises. Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products. The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25. Shares of Zydus Lifesciences fell 1.94% to Rs 888.45 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences has launched Aerolife Mini', a next-generation pMDI enhancer marking a significant step in the company's strategy to drive drug device led innovation that in respiratory care. Aerolife Mini' is India's first portable and foldable spacer, making it highly convenient to use. Zydus has launched this device under an exclusive licensing arrangement with AeroDel Technology Innovations. Aerolife Mini' introduces a compact, foldable, and ready to use design that fundamentally redefines how spacers are used. The drug device is expected to achieve better drug deposition, improve compliance enhance patient confidence and provide greater convenience. Powered by Capital Market - Live

CMS International Development and Management, a wholly-owned subsidiary of CMS, had secured an exclusive licence for the drug from Zydus in 2020. Desidustat, an oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), promotes red blood cell production by boosting endogenous erythropoietin and improving iron availability, targeting anaemia in Chronic Kidney Disease (CKD) patients. The drug is marketed in India under the brand name Oxemia, which has treated over 1 lakh (100,000) CKD patients since its 2022 launch. With an estimated 120 million CKD patients in China, there is significant unmet demand, particularly among non-dialysis patients, with only 8.2% achieving target haemoglobin levels. Oral Desidustat is expected to improve compliance and address treatment gaps in CKD-related anaemia in China. Speaking on the development, Managing Director of Zydus Lifesciences, Dr. Sharvil P. Patel, said, 'We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes globally. We are happy to partner with CMS and are confident it will expand access for CKD patients across Greater China.' Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products. The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25. Shares of Zydus Lifesciences fell 1.94% to Rs 888.45 on the BSE.Powered by Capital Market - Live

The drug is the generic version of Evoxac Capsules, 30 mg. It is indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sj'gren's syndrome and works as a muscarinic receptor agonist that stimulates salivary secretion. The capsules will be manufactured at the group's formulation facility at SEZ-II, Ahmedabad. According to IQVIA MAT January 2026 data, the product recorded annual sales of $26.9 million in the United States. With this approval, the group now has 436 USFDA approvals and has filed 505 ANDAs since it began filing in FY2003-04. Zydus Life Sciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing, and distribution of pharmaceutical products. The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25. Shares of Zydus Lifesciences fell 0.98% to Rs 907.50 on the BSE.Powered by Capital Market - Live